Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Dose Delays and Treatment Interruptions Secondary to Ocular Toxicity From BCMA-Directed Antibody Drug Conjugate Therapy in Relapsed Multiple Myeloma

Clinical Lymphoma Myeloma & Leukemia(2025)10.1016/j.clml.2025.10.003Source: DataRank Database

Dose Delays and Treatment Interruptions Secondary to Ocular Toxicity From BCMA-Directed Antibody Drug Conjugate Therapy in Relapsed Multiple Myeloma is a research paper published in Clinical Lymphoma Myeloma & Leukemia (2025). On theSindex it has a DataRank of 0.165. It has been cited 2 times.

N/A

0.165DataRank · unranked

Scored on demand from live citation data

Open Access2 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 2.45)OA: greenTopics (39)IDs (PubMed, PMC, OpenAlex)Annotations (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.165

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (22)

Timothy T. Xu ORCID,Suheil Albert Atallah‐Yunes ORCID,Kenneth J C Lim ORCID,Sikander Ailawadhi ORCID,Ricardo Parrondo ORCID

Live enrichment

PubMed:41162290 PMC:PMC13268594 OpenAlex:https://openalex.org/W4414838006

National Cancer Institute

Grant: U01CA271410

Paula and Rodger Riney Foundation

National Institutes of Health

Mayo Clinic

FWCI

2.45

Citation Percentile

0.9%

Citation Trend

2026

greenLicense: https://doi.org/10.15223/policy-004

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC13268594/

publisherhttps://api.elsevier.com/content/article/PII:S2152265025042314?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2152265025042314?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.clml.2025.10.003

Fields of Study

Multiple Myeloma Research and TreatmentsHER2/EGFR in Cancer ResearchMonoclonal and Polyclonal Antibodies ResearchHumansMultiple MyelomaMaleFemaleAgedImmunoconjugatesMiddle AgedRetrospective StudiesB-Cell Maturation AntigenAged, 80 and overAdultAntibodies, Monoclonal, Humanized

MeSH Terms

AdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedMultiple MyelomaRetrospective StudiesImmunoconjugatesB-Cell Maturation AntigenAntibodies, Monoclonal, Humanized

Keywords

DiscontinuationMultiple myelomaPhotophobiaToxicityDrugAntibody-drug conjugateAntibodyAdverse effectsKeratopathyMonoclonal GammopathyDose ModificationB-cell Maturation Antigen

Dose Delays and Treatment Interruptions Secondary to Ocular Toxicity From BCMA-Directed Antibody Drug Conjugate Therapy in Relapsed Multiple Myeloma

FAIR Checklist

DataRank Breakdown

Authors (22)

Funding (4 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)